Core Insights - Corcept Therapeutics presented data from the MOMENTUM trial, revealing that 27.3% of patients with resistant hypertension have hypercortisolism, indicating a significant prevalence of this condition in a challenging patient population [1][2][3] Group 1: MOMENTUM Trial Findings - The MOMENTUM trial screened 1,086 patients with resistant hypertension, identifying hypercortisolism in 297 patients, which is 27.3% of the total [2][5] - The trial's findings align with the CATALYST trial, which reported hypercortisolism in 23.8% of 1,057 patients with difficult-to-control type 2 diabetes [2] - Among patients with hemoglobin A1c (HbA1c) of 7.5% or higher taking three or more blood pressure medications, the prevalence of hypercortisolism was 32.6% in MOMENTUM and 36.6% in CATALYST [2] Group 2: Clinical Implications - Resistant hypertension is associated with increased risks of cardiovascular events, including heart attacks and strokes, as well as kidney damage [3] - The data suggests that screening for hypercortisolism in patients with resistant hypertension could lead to more personalized treatment approaches [3][4] - Corcept's Chief Development Officer emphasized the need for increased screening and improved treatment options based on the trial's findings [4] Group 3: Company Overview - Corcept Therapeutics focuses on cortisol modulation to treat various serious disorders and has developed over 1,000 proprietary selective cortisol modulators [8] - The company has introduced Korlym®, the first FDA-approved medication for endogenous Cushing's syndrome, and Lifyorli™, a selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer [8]